Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer
Standard
Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. / Lüftner, Diana; Hartkopf, Andreas D; Lux, Michael P; Overkamp, Friedrich; Tesch, Hans; Titzmann, Adriana; Pöschke, Patrik; Wallwiener, Markus; Müller, Volkmar; Beckmann, Matthias W; Belleville, Erik; Janni, Wolfgang; Fehm, Tanja N; Kolberg, Hans-Christian; Ettl, Johannes; Wallwiener, Diethelm; Schneeweiss, Andreas; Brucker, Sara Y; Fasching, Peter A.
in: BREAST CARE, Jahrgang 16, Nr. 2, 04.2021, S. 108-114.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer
AU - Lüftner, Diana
AU - Hartkopf, Andreas D
AU - Lux, Michael P
AU - Overkamp, Friedrich
AU - Tesch, Hans
AU - Titzmann, Adriana
AU - Pöschke, Patrik
AU - Wallwiener, Markus
AU - Müller, Volkmar
AU - Beckmann, Matthias W
AU - Belleville, Erik
AU - Janni, Wolfgang
AU - Fehm, Tanja N
AU - Kolberg, Hans-Christian
AU - Ettl, Johannes
AU - Wallwiener, Diethelm
AU - Schneeweiss, Andreas
AU - Brucker, Sara Y
AU - Fasching, Peter A
N1 - Copyright © 2021 by S. Karger GmbH, Freiburg.
PY - 2021/4
Y1 - 2021/4
N2 - Background: The therapeutic armamentarium for patients with metastatic breast cancer is becoming more and more specific. Recommendations from clinical trials are not available for all treatment situations and patient subgroups, and it is therefore important to collect real-world data.Summary: To develop recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research PRAEGNANT Network was established to optimize the quality of oncological care in the advanced therapeutic setting. The main aim of PRAEGNANT is to systematically record medical care for patients with metastatic breast cancer in the real-life setting, including the outcome and side effects of different treatment strategies, to monitor quality-of-life changes during therapy, to identify patients eligible for participation in clinical studies, and to allow targeted therapies based on the molecular structures of breast carcinomas.Key Messages: This article describes the PRAEGNANT network and sheds light on the question of whether the various end points from clinical trials can be transferred to the real-world treatment situation.
AB - Background: The therapeutic armamentarium for patients with metastatic breast cancer is becoming more and more specific. Recommendations from clinical trials are not available for all treatment situations and patient subgroups, and it is therefore important to collect real-world data.Summary: To develop recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research PRAEGNANT Network was established to optimize the quality of oncological care in the advanced therapeutic setting. The main aim of PRAEGNANT is to systematically record medical care for patients with metastatic breast cancer in the real-life setting, including the outcome and side effects of different treatment strategies, to monitor quality-of-life changes during therapy, to identify patients eligible for participation in clinical studies, and to allow targeted therapies based on the molecular structures of breast carcinomas.Key Messages: This article describes the PRAEGNANT network and sheds light on the question of whether the various end points from clinical trials can be transferred to the real-world treatment situation.
U2 - 10.1159/000515701
DO - 10.1159/000515701
M3 - SCORING: Review article
C2 - 34007260
VL - 16
SP - 108
EP - 114
JO - BREAST CARE
JF - BREAST CARE
SN - 1661-3791
IS - 2
ER -